BioSpace News Archive

Business

Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results

As at September 30, 2017, Arbutus had cash, cash equivalents, short-term investments and restricted investments totaling $100.8 million, as compared to $143.2 million at December 31, 2016.

November 3, 2017

·

19 min read

Business

CluePoints Builds on Late Phase Work in Japan and Launches Risk-Based Monitoring Roadshow in Tokyo

The collaborations mark the latest success for CluePoints in the region, with its centralized statistical monitoring (CSM) platform having already been used by the Nagoya University School of Medicine for an eight-year Phase III Stomach Cancer Adjuvant Multi-Institutional Group Trial (SAMIT).

November 3, 2017

·

3 min read

Deals

Celonic Acquires Glycotope’s Bio-manufacturing Facility

The acquisition is in line with Celonic’s vision to strengthen its position as a premier global player in the high-growth CDMO market, with continued investment in strategic assets and innovative technology platforms.

November 3, 2017

·

3 min read

Policy

Government Plan for New Treatments Welcomed By Alzheimer’s Research UK

The plan takes forward several recommendations from last year’s Accelerated Access Review – which examined how advances in medicine could be made available to patients faster – and could have major implications for future dementia treatments.

November 3, 2017

·

2 min read

Policy

The Biosimilars Forum applauds the Centers for Medicare and Medicaid Services (CMS) decision to reverse the existing policy on biosimilar reimbursement that has been in effect since January 1, 2016.

November 3, 2017

·

1 min read

Business

Perrigo Encourages Tobacco-Free Living Through Partnership With American Cancer Society

American Cancer Society resources available through its partnership with Perrigo provide consumers with an effective roadmap to living tobacco-free.

November 3, 2017

·

2 min read

Genetown

Akebia Reports Inducement Grant to Three Newly-Hired Employees Entering Into Employment With the Company Under NASDAQ Listing Rule 5635(C)(4)

Akebia announced that the Company granted three newly-hired employees options to purchase an aggregate of 44,500 shares of Akebia’s common stock with a per share exercise price of $18.15, the closing price on the grant date.

November 3, 2017

·

1 min read

BioCapital

Aziyo Launches CanGaroo Bio Envelope for Subcutaneous Implantable Cardioverter-Defibrillators

November 3, 2017

·

3 min read

Genetown

Eleven Biotherapeutics Announces Closing of $8M Underwritten Public Offering

The company announced the closing of the previously announced underwritten public offering of 5,525,000 shares of its common stock.

November 3, 2017

·

5 min read

Drug Development

Vertex’s Phase III Studies of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis Ages 12 and Older Published in the New England Journal of Medicine

In both studies, the tezacaftor/ivacaftor combination demonstrated statistically significant and clinically meaningful improvements in lung function and other measures of disease.

November 3, 2017

·

14 min read